866208-24-4

Basic information

• Product Name: 7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one
• CAS NO: 866208-24-4
• Molecular Formula: C₁₀H₁₀FNO
• Molecular Weight: 179.1909
• Mol File: 866208-24-4.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 289.408°C at 760 mmHg
• Flash Point: 128.829°C
• Density: 1.166g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.519
• CAS DataBase Reference: 7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one(866208-24-4)
• EPA Substance Registry System: 7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one(866208-24-4)

Safety Data

• Hazardous Substances Data: 866208-24-4(Hazardous Substances Data)

Upstream product

• 913720-03-3 2-(2,3-difluorophenyl)isobutyramide 
• 913720-04-4 2-(2,6-difluorophenyl)isobutyramide 
• 71294-03-6 7-fluoro-1,3-dihydro-indol-2-one 
• 74-88-4 methyl iodide 

Downstream Products

• 866209-70-3 7-fluoro-1-[(1S,2S)-1-(3-fluorophenyl)-2,3-dihydroxypropyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 929564-72-7 7-fluoro-1-(3-fluorobenzyl)-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 872141-26-9 5-bromo-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 929564-91-0 1-[(1R)-3-chloro-1-phenylpropyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 929565-60-6 1-[(1R)-3-chloro-1-(3,5-difluorophenyl)propyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 
• 929565-62-8 1-[(1R)-3-chloro-1-(3-chlorophenyl)propyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 

Relevant articles and documents

1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors

Efforts to identify new selective and potent norepinephrine reuptake inhibitors (NRIs) for multiple indications by structural modification of the previous 3-(arylamino)-3-phenylpropan-2-olamine scaffold led to the discovery of a novel series of 1-(indolin-1-yl)-1-phenyl-3-propan-2-olamines (9). Investigation of the structure-activity relationships revealed that small alkyl substitution at the C3 position of the indoline ring enhanced selectivity for the norepinephrine transporter (NET) over the serotonin transporter (SERT). Several compounds bearing a 3, 3-dimethyl group on the indoline ring, 9k, 9o,p, and 9s,t, exhibited potent inhibition of NET (IC50= 2.7-6.5 nM) and excellent selectivity over both serotonin and dopamine transporters. The best example from this series, 9p, a potent and highly selective NRI, displayed oral efficacy in a telemetric rat model of ovariectomized-induced thermoregulatory dysfunction, a mouse p-phenylquinone (PPQ) model of acute visceral pain, and a rat spinal nerve ligation (SNL) model of neuropathic pain.

DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to dihydrobenzofuranyl derivatives of formula I: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.

Phenylaminopropanol derivatives and methods of their use

The present invention is directed to phenylaminopropanol derivatives of formulae I, II, and III: [image] or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, schizophrenia, and combinations thereof.